The next focusIR Investor Webinar takes places on 14th May with guest speakers from Blue Whale Growth Fund, Taseko Mines, Kavango Resources and CQS Natural Resources fund. Please register here.

Less Ads, More Data, More Tools Register for FREE

Pin to quick picksTristel Regulatory News (TSTL)

Share Price Information for Tristel (TSTL)

London Stock Exchange
Share Price is delayed by 15 minutes
Get Live Data
Share Price: 462.50
Bid: 455.00
Ask: 470.00
Change: 0.00 (0.00%)
Spread: 15.00 (3.297%)
Open: 0.00
High: 0.00
Low: 0.00
Prev. Close: 462.50
TSTL Live PriceLast checked at -

Watchlists are a member only feature

Login to your account

Alerts are a premium feature

Login to your account

Director/PDMR Dealing and Issue of Equity

2 May 2018 16:55

RNS Number : 9416M
Tristel PLC
02 May 2018
 

 

Tristel plc

("Tristel" or the "Company")

Director/PDMR Dealing and Issue of Equity

Tristel plc (AIM: TSTL), the manufacturer of infection prevention, contamination control and hygiene products, announces that on 2 May 2018 the Company has issued and allotted 140,000 new ordinary shares of 1 penny each in the Company ("Ordinary Shares"), following the exercise of 140,000 Ordinary Shares by Liz Dixon, Finance Director, at a weighted average exercise price of 56 pence per share. A number of the share options were due to expire in July 2018.

Liz Dixon subsequently sold 140,000 Ordinary Shares at a price of 300 pence per share. Liz Dixon's resultant holding is 45,000 Ordinary Shares representing 0.1% of the issued share capital of the Company and options over 709,888 Ordinary Shares.

Of the new Ordinary Shares sold, Francisco Soler acquired 60,000 Ordinary Shares at 300 pence per share. Francisco Soler's resultant holding is 8,473,834 Ordinary Shares (includes family and related corporate vehicles) representing 19.6% of the issued share capital of the Company.

Application has been made for the new Ordinary Shares to be admitted to trading on AIM and dealings are expected to commence on 9 May 2018. The new Ordinary Shares will rank pari passu with the existing shares of the Company. Following the exercise of options, the Company's issued share capital consists of 43,167,633 Ordinary Shares. Accordingly, the figure of 43,167,633 may be used by shareholders as the denominator for the calculations by which they will determine if they are required to notify their interest in, or a change to their interest in the Company under the FCA's Disclosure Guidance and Transparency Rules.

For further information please contact:

 

Tristel plc

Tel: 01638 721 500

Paul Swinney, Chief Executive Officer

Liz Dixon, Finance Director

Walbrook PR Ltd

Tel: 020 7933 8780 or tristel@walbrookpr.com

Paul McManus

Mob: 07980 541 893

Lianne Cawthorne

Mob: 07854 391 303

finnCap

Tel: 020 7220 0500

Geoff Nash (Corporate Finance)

Giles Rolls (Corporate Finance)

Alice Lane (Corporate Broking)

 

 

 

Notification and public disclosure of transactions by persons discharging managerial responsibilities and persons closely associated with them

 

1.

Details of the person discharging managerial responsibilities / person closely associated

a)

Name

Liz Dixon

2.

Reason for the Notification

a)

Position/status

Director / PDMR

b)

Initial notification/Amendment

Initial notification

3.

Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor

a)

Name

Tristel plc

b)

LEI

2138009DZ4LH9CZGF662

4.

Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transactions have been conducted

a)

Description of the Financial instrument, type of instrument

 

Ordinary shares of 1p

Identification code

GB00B07RVT99

b)

Nature of the transaction

Exercise of options over Ordinary Shares and

Sale of Ordinary Shares

c)

Price(s) and volume(s)

Exercise of Options

Exercise Price(s)

Volume(s)

£0.5375

£0.5375

£0.5375

£0.79

60,000

60,000

10,000

10,000

 

Sale of Ordinary Shares

 

Price(s)

Volume(s)

£3.00

140,000

d)

Aggregated information:

· Aggregated volume

· Price

See above

e)

Date of the transaction

2 May 2018

f)

Place of the transaction

London Stock Exchange, AIM Market (XLON)

 

 

1.

Details of the person discharging managerial responsibilities / person closely associated

a)

Name

Francisco Soler (through World Financial Trading Corporation and Atlas World Carriers S.A.)

2.

Reason for the Notification

a)

Position/status

Director / PDMR

b)

Initial notification/Amendment

Initial notification

3.

Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor

a)

Name

Tristel plc

b)

LEI

2138009DZ4LH9CZGF662

4.

Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transactions have been conducted

a)

Description of the Financial instrument, type of instrument

 

Ordinary shares of 1p

Identification code

GB00B07RVT99

b)

Nature of the transaction

 

Purchase of Ordinary Shares

c)

Price(s) and volume(s)

World Financial Trading Corporation

Price(s)

Volume(s)

£3.00

30,000

Atlas World Carriers S.A.

Price(s)

Volume(s)

£3.00

30,000

d)

Aggregated information:

· Aggregated volume

· Price

 

Purchase of 60,000 ordinary shares of 1p pence at 300 pence per Ordinary Share

e)

Date of the transaction

2 May 2018

f)

Place of the transaction

London Stock Exchange, AIM Market (XLON)

 

 

The information communicated in this announcement is inside information for the purposes of Article 7 of Regulation 596/2014

 

This information is provided by RNS
The company news service from the London Stock Exchange
 
END
 
 
DSHFKBDPPBKDNPK
Date   Source Headline
16th Apr 20242:04 pmRNSDirector/PDMR Shareholding
15th Apr 20245:56 pmRNSExercise of Share Options and Total Voting Rights
19th Mar 20249:25 amRNSExercise of Share Options and Total Voting Rights
27th Feb 20247:00 amRNSExercise of Share Options and Total Voting Rights
26th Feb 20247:01 amRNSHalf-year Report
26th Feb 20247:00 amRNSUK and EU regulatory approval update
8th Feb 20247:00 amRNSExercise of Share Options and Total Voting Rights
1st Feb 20247:00 amRNSNotice of Interim Results
25th Jan 20247:00 amRNSExercise of Share Options and Total Voting Rights
23rd Jan 20247:00 amRNSCanadian regulatory approval for Tristel ULT
10th Jan 20242:27 pmRNSDirector/PDMR Shareholding
19th Dec 202312:02 pmRNSResult of AGM
19th Dec 20237:00 amRNSAGM Statement
7th Dec 20232:05 pmRNSExercise of Share Options and Total Voting Rights
1st Dec 20237:00 amRNSExercise of Share Options and Total Voting Rights
29th Nov 202312:40 pmRNSExercise of Share Options and Total Voting Rights
7th Nov 202311:00 amRNSExercise of Share Options and Total Voting Rights
16th Oct 20237:00 amRNSAudited Preliminary Results
12th Oct 20237:00 amRNSAdditional Investor Presentation
10th Oct 20234:45 pmRNSExercise of Share Options and Total Voting Rights
2nd Oct 202311:50 amRNSHolding(s) in Company
28th Sep 20232:00 pmRNSExercise of Share Options and Total Voting Rights
26th Sep 20232:40 pmRNSHolding(s) in Company
25th Sep 20238:40 amRNSHolding(s) in Company
22nd Sep 20233:40 pmRNSHolding(s) in Company
12th Sep 20237:00 amRNSNotice of Results
4th Sep 20237:00 amRNSHealth Canada regulatory approval submission
31st Jul 20238:05 amRNSHolding(s) in Company
28th Jul 20238:28 amRNSDirector/PDMR Shareholding
25th Jul 20237:00 amRNSTrading update
12th Jul 20237:00 amRNSShareholder Open Day and Notice of Trading Update
10th Jul 20237:00 amRNSExercise of Share Options and Total Voting Rights
26th Jun 20237:00 amRNSDirector/PDMR Shareholding
22nd Jun 20234:01 pmRNSHolding(s) in Company
16th Jun 20237:00 amRNSExercise of Share Options and Total Voting Rights
14th Jun 20234:10 pmRNSHolding(s) in Company
6th Jun 20235:00 pmRNSExercise of Share Options and Total Voting Rights
5th Jun 202310:00 amRNSAnalyst and Investor presentation
5th Jun 20237:00 amRNSFDA De Novo approval
28th Mar 202311:30 amRNSIssue of Equity
27th Mar 20237:00 amRNSSuccessful submission of additional data to US FDA
14th Mar 20232:05 pmRNSSecond Price Monitoring Extn
14th Mar 20232:00 pmRNSPrice Monitoring Extension
14th Mar 20239:30 amRNSIssue of Equity
22nd Feb 20234:30 pmRNSIssue of Equity
20th Feb 20237:00 amRNSHalf-year Report
30th Jan 20237:00 amRNSNotice of Results and Investor presentation
14th Dec 202211:00 amRNSResult of AGM - Replacement
13th Dec 20227:00 amRNSIssue of Equity
12th Dec 202211:26 amRNSResult of AGM

Due to London Stock Exchange licensing terms, we stipulate that you must be a private investor. We apologise for the inconvenience.

To access our Live RNS you must confirm you are a private investor by using the button below.

Login to your account

Don't have an account? Click here to register.

Quickpicks are a member only feature

Login to your account

Don't have an account? Click here to register.